CoChat

ROCK 1 is a potential combinatorial drug target for BRAF mutant melanoma

Open access
Smit, Marjon A, Maddalo, Gianluca, Greig, Kylie, Raaijmakers, Linsey M, Possik, Patricia A, van Breukelen, Bas, Cappadona, Salvatore, Heck, Albert JR, Altelaar, AF Maarten, Peeper, Daniel S · 2014 · Molecular Systems Biology
Cited by 54

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Treatment of BRAF mutant melanomas with specific BRAF inhibitors leads to tumor remission. However, most patients eventually relapse due to drug resistance. Therefore, we designed an integrated strategy using (phospho)proteomic and functional genomic platforms to identify drug targets whose inhibition sensitizes melanoma cells to BRAF inhibition. We found many proteins to be induced upon PLX 4720 ( BRAF inhibitor) treatment that are known to be involved in BRAF inhibitor resistance, including FOXD 3 and ErbB3. Several proteins were down‐regulated, including Rnd3, a negative regulator of ROCK 1 kinase. For our genomic approach, we performed two parallel sh RNA screens using a kinome library to identify genes whose inhibition sensitizes to BRAF or ERK inhibitor treatment. By integrating our functional genomic and (phospho)proteomic data, we identified ROCK 1 as a potential drug target for BRAF mutant melanoma. ROCK 1 silencing increased melanoma cell elimination when combined with BRAF or ERK inhibitor treatment. Translating this to a preclinical setting, a ROCK inhibitor showed augmented melanoma cell death upon BRAF or ERK inhibition in vitro . These data merit exploration of ROCK 1 as a target in combination with current BRAF mutant melanoma therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/msb.20145450

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 54

Metadata

Authors
Smit, M. A., Maddalo, G., Greig, K., Raaijmakers, L. M., Possik, P. A., van Breukelen, B., Cappadona, S., Heck, A. J., Altelaar, A. M., & Peeper, D. S.
Venue
Molecular Systems Biology
Published
2014-12
Volume
10
Issue
12
Pages
772-772
ISSN
1744-4292 (ISSN-L)
OpenAlex
W2105498651
Cited by
54
References
16
FWCI
3.04
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ROCK 1 is a potential combinatorial drug target for BRAF mutant melanoma. https://app.cochat.ai/papers/10.15252/msb.20145450
The paper
Smit, M. A., Maddalo, G., Greig, K., Raaijmakers, L. M., Possik, P. A., van Breukelen, B., Cappadona, S., Heck, A. J., Altelaar, A. M., & Peeper, D. S. (2014). ROCK 1 is a potential combinatorial drug target for BRAF mutant melanoma. Molecular Systems Biology. https://doi.org/10.15252/msb.20145450

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.